An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma
Abstract Background Metabolic reprogramming, particularly upregulated de novo pyrimidine biosynthesis, drives cancer progression and immune evasion. Dihydroorotate dehydrogenase (DHODH), a key enzyme in this pathway, is a promising therapeutic target, but its inhibitors often face resistance in immu...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2025-11-01
|
| Schriftenreihe: | Journal of Experimental & Clinical Cancer Research |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s13046-025-03566-6 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|